For research and educational purposes only. Not medical advice.

FIT Stack Reference

Educational, not medical advice reference for FIT Stack: GH Release; regulatory status, evidence posture, source review, and schedule notes. Als…

Plain English

What it is
FIT Stack is a nickname for two lab-made peptides sold together in one product: CJC-1295 and ipamorelin. Both are research chemicals, not approved medicines, and together they are meant to nudge the body to release more of its own growth hormone in natural bursts.
What people use it for
In the peptide community this is the classic growth-hormone-pulse combo. People reach for it hoping for better sleep, faster recovery, and slow changes in body composition. The idea is that the two peptides work better together than alone, but this is based on personal stories, not approved medical use.
What the science shows
The two peptides have never been tested together in a real study, so the combo itself is unproven. On their own, each has only small, short-term human studies showing they can raise growth hormone. There is little data on long-term results or safety, so most of what people report stays anecdotal.
The catch
Neither peptide is FDA-approved, and neither is hormone replacement. The FDA has flagged safety concerns for compounded peptides like these, and an FDA advisory committee reviewed ipamorelin for pharmacy compounding rather than approving it. Pushing growth hormone and IGF-1 up can cause water retention, joint aches, tingling, and blood-sugar changes, and unapproved vials have no quality checks.

Reference summary

There are no published studies of CJC-1295 and ipamorelin given together as a fixed blend. Each ingredient has only small, short-term human work: a healthy-men study of the long-acting DAC form of CJC-1295 raised growth hormone and IGF-1 while preserving pulsatility, and early human PK/PD work confirmed ipamorelin triggers growth-hormone release. Long-term outcome and safety data are limited for both, and the pulse-matched pairing rests on mechanism reasoning rather than combination trials.

Regulatory and posture

Categories
GH Release
Aliases
FIT Stack, CJC-1295 / Ipamorelin, CJC-1295 no DAC + Ipamorelin, CJC-1295 and Ipamorelin blend, CJC + Ipa
Evidence posture
preclinical - No studies test this pairing as a blend. The individual ingredients have only small, short-term human growth-hormone-pulse studies, with limited long-term data.
Regulatory status
No FDA-approved drug label exists for the CJC-1295 plus ipamorelin blend or for either ingredient. The combination, sometimes sold under blend names such as FIT Stack, has never been reviewed or approved by any regulator. FDA lists CJC-1295 among bulk substances with safety-risk concerns for compounding, and in September 2024 FDA's Pharmacy Compounding Advisory Committee considered ipamorelin for the section 503A Bulks List, so its compounding status is under active FDA review. Both remain not FDA-approved, and neither is hormone replacement therapy.
Content review status
research reference

Selected public sources

Related tools